{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:53Z","timestamp":1781632493540,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011282","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000}}],"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institut Pasteur"},{"name":"Urgence COVID-19 Fundraising Campaign of Institut Pasteur"},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vaccine Research Institute","award":["ANR-10-LABX-77"],"award-info":[{"award-number":["ANR-10-LABX-77"]}]},{"name":"Labex IBEID","award":["ANR-10-LABX-62-IBEI"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEI"]}]},{"name":"ANR \/ FRM Flash Covid PROTEO-SARS-CoV-2"},{"name":"ANR Coronamito"},{"name":"HERA european funding"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IDISCOVR"},{"name":"EMERGEN","award":["ANRS0151"],"award-info":[{"award-number":["ANRS0151"]}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Investissements d\u2019Avenir program, Vaccine Research Institute","award":["ANR-10-LABX-77-01"],"award-info":[{"award-number":["ANR-10-LABX-77-01"]}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Because SARS-CoV-2 constantly mutates to escape from the immune response, there is a reduction of neutralizing capacity of antibodies initially targeting the historical strain against emerging Variants of Concern (VoC)s. That is why the measure of the protection conferred by vaccination cannot solely rely on the antibody levels, but also requires to measure their neutralization capacity. Here we used a mathematical model to follow the humoral response in 26 individuals that received up to three vaccination doses of Bnt162b2 vaccine, and for whom both anti-S IgG and neutralization capacity was measured longitudinally against all main VoCs. Our model could identify two independent mechanisms that led to a marked increase in measured humoral response over the successive vaccination doses. In addition to the already known increase in IgG levels after each dose, we identified that the neutralization capacity was significantly increased after the third vaccine administration against all VoCs, despite large inter-individual variability. Consequently, the model projects that the mean duration of detectable neutralizing capacity against non-Omicron VoC is between 348 days (Beta variant, 95% Prediction Intervals PI [307; 389]) and 587 days (Alpha variant, 95% PI [537; 636]). Despite the low neutralization levels after three doses, the mean duration of detectable neutralizing capacity against Omicron variants varies between 173 days (BA.5 variant, 95% PI [142; 200]) and 256 days (BA.1 variant, 95% PI [227; 286]). Our model shows the benefit of incorporating the neutralization capacity in the follow-up of patients to better inform on their level of protection against the different SARS-CoV-2 variants.<\/jats:p>\n<jats:p><jats:bold>Trial registration<\/jats:bold>: This clinical trial is registered with ClinicalTrials.gov, Trial IDs <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04750720\" xlink:type=\"simple\">NCT04750720<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05315583\" xlink:type=\"simple\">NCT05315583<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1011282","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:33:02Z","timestamp":1691429582000},"page":"e1011282","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-3859","authenticated-orcid":true,"given":"Quentin","family":"Clairon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Prague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Bruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-3962","authenticated-orcid":true,"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":true,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"9","key":"pcbi.1011282.ref001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"OJ Watson","year":"2022","journal-title":"The Lancet Infectious Diseases"},{"issue":"19","key":"pcbi.1011282.ref002","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"SJ Thomas","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pcbi.1011282.ref003","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"FP Polack","year":"2020","journal-title":"New England journal of medicine"},{"key":"pcbi.1011282.ref004","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"LR Baden","year":"2020","journal-title":"New England journal of medicine"},{"issue":"8","key":"pcbi.1011282.ref005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJMc2107717","article-title":"Effect of vaccination on household transmission of SARS-CoV-2 in England","volume":"385","author":"RJ Harris","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"pcbi.1011282.ref006","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"E Pritchard","year":"2021","journal-title":"Nature medicine"},{"issue":"8","key":"pcbi.1011282.ref007","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 vaccination on transmission of alpha and delta variants","volume":"386","author":"DW Eyre","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"pcbi.1011282.ref008","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","article-title":"Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States: Study examines role of COVID-19 vaccines and deaths averted in the United States","volume":"40","author":"S Gupta","year":"2021","journal-title":"Health Affairs"},{"issue":"47","key":"pcbi.1011282.ref009","doi-asserted-by":"crossref","first-page":"2101021","DOI":"10.2807\/1560-7917.ES.2021.26.47.2101021","article-title":"Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021","volume":"26","author":"MM Mesl\u00e9","year":"2021","journal-title":"Eurosurveillance"},{"issue":"7898","key":"pcbi.1011282.ref010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"S Cele","year":"2022","journal-title":"Nature"},{"issue":"7871","key":"pcbi.1011282.ref011","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"D Planas","year":"2021","journal-title":"Nature"},{"key":"pcbi.1011282.ref012","article-title":"Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant","author":"JL Bernal","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"pcbi.1011282.ref013","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pcbi.1011282.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"B Mizrahi","year":"2021","journal-title":"Nature communications"},{"issue":"24","key":"pcbi.1011282.ref015","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Y Goldberg","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"pcbi.1011282.ref016","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"EG Levin","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"pcbi.1011282.ref017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"D Cromer","year":"2021","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"pcbi.1011282.ref018","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2666-5247(21)00307-4","article-title":"WHO international standard for SARS-CoV-2 antibodies to determine markers of protection","volume":"3","author":"F Zhu","year":"2022","journal-title":"The Lancet Microbe"},{"issue":"1","key":"pcbi.1011282.ref019","doi-asserted-by":"crossref","first-page":"21232","DOI":"10.1038\/s41598-022-25134-0","article-title":"Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex","volume":"12","author":"CS Korosec","year":"2022","journal-title":"Scientific Reports"},{"issue":"5","key":"pcbi.1011282.ref020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies","volume":"27","author":"D Planas","year":"2021","journal-title":"Nature medicine"},{"key":"pcbi.1011282.ref021","article-title":"Duration of BA. 5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection","author":"D Planas","year":"2022","journal-title":"Med"},{"issue":"18","key":"pcbi.1011282.ref022","doi-asserted-by":"crossref","first-page":"e00579","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamic of the humoral immune response to a prime-boost Ebola vaccine: quantification and source of variation","volume":"93","author":"C Pasin","year":"2019","journal-title":"Journal of Virology"},{"key":"pcbi.1011282.ref023","doi-asserted-by":"crossref","first-page":"110254","DOI":"10.1016\/j.jtbi.2020.110254","article-title":"A model for establishment, maintenance and reactivation of the immune response after two-dose vaccination regimens against Ebola virus","author":"I Balelli","year":"2020","journal-title":"Journal of Theoretical Biology"},{"key":"pcbi.1011282.ref024","article-title":"Increased potency and breadth of SARS-CoV-2 neutralizing antibodies after a third mRNA vaccine dose","author":"F Muecksch","year":"2022","journal-title":"bioRxiv"},{"issue":"7903","key":"pcbi.1011282.ref025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-022-04466-x","article-title":"Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants","volume":"603","author":"K Wang","year":"2022","journal-title":"Nature"},{"issue":"2","key":"pcbi.1011282.ref026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","article-title":"Modeling how antibody responses may determine the efficacy of COVID-19 vaccines","volume":"2","author":"P Padmanabhan","year":"2022","journal-title":"Nature Computational Science"},{"issue":"450","key":"pcbi.1011282.ref027","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/01621459.2000.10474219","article-title":"On profile likelihood","volume":"95","author":"SA Murphy","year":"2000","journal-title":"Journal of the American Statistical Association"},{"key":"pcbi.1011282.ref028","unstructured":"Lixoft. Monolix version 2020R1. Antony, France. 2020;."},{"issue":"3","key":"pcbi.1011282.ref029","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model","volume":"51","author":"A Samson","year":"2006","journal-title":"Computational Statistics & Data Analysis"},{"issue":"11","key":"pcbi.1011282.ref030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"S Feng","year":"2021","journal-title":"Nature medicine"},{"issue":"6576","key":"pcbi.1011282.ref031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"PB Gilbert","year":"2022","journal-title":"Science"},{"key":"pcbi.1011282.ref032","doi-asserted-by":"crossref","first-page":"e75427","DOI":"10.7554\/eLife.75427","article-title":"Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection","volume":"11","author":"M Alexandre","year":"2022","journal-title":"Elife"},{"key":"pcbi.1011282.ref033","first-page":"12","article-title":"Estimating censored regression models in R using the censReg Package","volume":"5","author":"A Henningsen","year":"2010","journal-title":"R package vignettes"},{"issue":"58","key":"pcbi.1011282.ref034","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"RR Goel","year":"2021","journal-title":"Science immunology"},{"key":"pcbi.1011282.ref035","first-page":"1098","volume-title":"MAbs","author":"BJ Booth","year":"2018"},{"key":"pcbi.1011282.ref036","first-page":"5064","article-title":"Increased B cell selection stringency in germinal centers can explain improved COVID-19 vaccine efficacies with low dose prime or delayed boost","author":"AK Garg","year":"2021","journal-title":"Frontiers in immunology"},{"key":"pcbi.1011282.ref037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.998262","article-title":"In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose","volume":"13","author":"P Stolfi","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"pcbi.1011282.ref038","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/infdis\/jiab592","article-title":"Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults","volume":"225","author":"MA Brockman","year":"2022","journal-title":"The Journal of Infectious Diseases"},{"key":"pcbi.1011282.ref039","article-title":"Serial infection with SARS-CoV-2 Omicron BA. 1 and BA. 2 following three-dose COVID-19 vaccination","author":"HR Lapointe","year":"2022","journal-title":"medRxiv"},{"key":"pcbi.1011282.ref040","first-page":"2023","article-title":"Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics: implications to define correlates of protection against infection","author":"G Lingas","year":"2023","journal-title":"medRxiv"},{"issue":"1","key":"pcbi.1011282.ref041","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41541-022-00586-7","article-title":"Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants","volume":"7","author":"TT Tran","year":"2022","journal-title":"npj Vaccines"},{"key":"pcbi.1011282.ref042","doi-asserted-by":"crossref","first-page":"113197","DOI":"10.1016\/j.jim.2021.113197","article-title":"Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects","volume":"500","author":"A Manenti","year":"2022","journal-title":"Journal of Immunological Methods"},{"issue":"4","key":"pcbi.1011282.ref043","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"C Li","year":"2022","journal-title":"Nature Immunology"},{"key":"pcbi.1011282.ref044","article-title":"Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose","author":"F Mwimanzi","year":"2022","journal-title":"medRxiv"},{"key":"pcbi.1011282.ref045","article-title":"Brief Report: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine","author":"FM Mwimanzi","year":"2022","journal-title":"medRxiv"},{"key":"pcbi.1011282.ref046","doi-asserted-by":"crossref","first-page":"101576","DOI":"10.1016\/j.eclinm.2022.101576","article-title":"Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study","volume":"51","author":"T Bruel","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"23","key":"pcbi.1011282.ref047","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"E Hacisuleyman","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10325","key":"pcbi.1011282.ref048","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"C Kuhlmann","year":"2022","journal-title":"The Lancet"},{"issue":"14","key":"pcbi.1011282.ref049","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron","volume":"386","author":"G Regev-Yochay","year":"2022","journal-title":"New England Journal of Medicine"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011282","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T17:56:16Z","timestamp":1692294976000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011282"}},"subtitle":[],"editor":[{"given":"James R.","family":"Faeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011282","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1011282","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}